...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Fas ligand expression is a risk factor for liver metastasis in colorectal cancer with venous invasion.
【24h】

Fas ligand expression is a risk factor for liver metastasis in colorectal cancer with venous invasion.

机译:Fas配体表达是大肠癌伴静脉浸润肝转移的危险因素。

获取原文
获取原文并翻译 | 示例
           

摘要

The expression of Fas ligand (Fas L) was investigated in sixty-seven patients with colorectal cancer for possible correlation with liver metastasis. Fas L expression was positive in 48 and negative in 19 cases. In Fas L-positive cases, 14 patients had liver metastasis including metachronous metastasis. However, only one case had liver metastasis in Fas L-negative patients (p = 0.0344). In colorectal cancer with venous invasion, 13 from 25 Fas L-positive cases had liver metastasis but only one in 19 negative cases (p = 0.0003). In the cases without venous invasion, no liver metastasis was observed in Fas L-negative cases. These results suggest that Fas L expression may be a predictive factor for liver metastasis in colorectal cancer with venous invasion.
机译:Fas配体(Fas L)的表达在67例结直肠癌患者中进行了研究,可能与肝转移有关。 Fas L表达阳性48例,阴性19例。在Fas L阳性病例中,有14例患者发生肝转移,包括异时转移。但是,在Fas L阴性患者中只有1例发生肝转移(p = 0.0344)。在患有静脉浸润的大肠癌中,Fas L阳性25例中有13例发生肝转移,但19例阴性中只有1例发生肝转移(p = 0.0003)。在无静脉浸润的情况下,在Fas L阴性病例中未观察到肝转移。这些结果表明,Fas L表达可能是大肠癌伴静脉浸润肝转移的预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号